HomeProductsBioactive CompoundsEndocrine & Hormonal TargetsACEOmapatrilat
Chemical structure of CAS 167305-00-2

Omapatrilat

In Stock•Starting at $54 for 1 mg•Purity ≥ 99.88%
CAS No.167305-00-2
MDL No.N/A
MFC19H24N2O4S2
MW408.50
InChI KeyLVRLSYPNFFBYCZ-VGWMRTNUSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mgTo Be Confirmed$54In Stock
5 mg99.88%$235In Stock
10 mg99.88%$408In Stock
25 mg99.88%$861In Stock
50 mg99.88%$1543In Stock
100 mg99.88%$2751In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Omapatrilat is a dipeptide.

CAS No.167305-00-2
Product NameOmapatrilat
Heavy Atom Count27Rotatable Bond Count5
Atom Stereo Count4Bond Stereo Count0
HBA5HBD3
TPSA86.710 ŲCharge0
Exact Mass408.11775Complexity700.21
pKa4.405XLogP1.941

Related Articles

Studies related to this compound and its mechanism of action

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.

British journal of pharmacology • Vol. 153, Issue 5 • 2008
PMID: 18084312PMC: PMC2267285DOI: 10.1038/sj.bjp.0707641

Omapatrilat enhances adrenomedullin's reduction of cardiomyocyte cell death.

European journal of pharmacology • Vol. 562, Issue 3 • 2007
PMID: 17343842DOI: 10.1016/j.ejphar.2007.01.056

Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.

European journal of pharmacology • Vol. 519, Issue 3 • 2005
PMID: 16137672DOI: 10.1016/j.ejphar.2005.07.015

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.

American journal of hypertension • Vol. 17, Issue 2 • 2004
PMID: 14751650DOI: 10.1016/j.amjhyper.2003.09.014

Documentation